Opko Health Inc
USUSDOpko Health Inc (LSE:0KCS) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- opko.com
- Investor relations
- opko.com/investors
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Headquarters
- Miami, United States
- Management
- Phillip Frost
- Latest reports
- Employees
- 2 275
- Founded
- 1991
- Shares outstanding
- 746.33 M as of 2026-07-17
- Free float
- 323.73 M
- Market cap
- 1.17 B USD
- Insiders
- 50.52%
- Institutions
- 27.56%
- Industry (SIC)
- Pharmaceutical Preparations
- Legal form
- Corporation
- ISIN
- US68375N1037
- LEI
- 529900A4S2D4OGOJLL02
- P/E
- loss
- P/B
- 2.05
- FCF
- −134 M USD
- Debt
- 349 M USDnegative FCF — not covered
- Earnings and FCF — for the 12 months to 30.06.2026 (the company's latest report).
- NAV
Description
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
News this week
Press releases from the company's investor website, updated daily. Links lead to the company's website. Headlines are in the original language, as on the company website.
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| Rubric Capital Managemen… | 6.4% | 47.79 M | 2026-06-30 |
| Blackrock Inc. | 4.95% | 36.98 M | 2026-06-30 |
| Vanguard Capital Managem… | 2.01% | 14.97 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 2% | 14.93 M | 2026-06-30 |
| Geode Capital Management… | 1.55% | 11.58 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 1.38% | 10.32 M | 2026-08-31 |
| State Street Corporation | 1.38% | 10.31 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.31% | 9.75 M | 2026-06-30 |
| Goldman Sachs Group Inc | 0.94% | 7.04 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.93% | 6.92 M | 2026-06-30 |
| UBS Group AG | 0.67% | 5.01 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.66% | 4.91 M | 2026-06-30 |
| Whitefort Capital Manage… | 0.6% | 4.51 M | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.58% | 4.35 M | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.51% | 3.79 M | 2026-08-31 |
| Northern Trust Corporati… | 0.5% | 3.76 M | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.38% | 2.81 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.29% | 2.2 M | 2026-06-30 |
| VANGUARD SCOTTSDALE FUND… | 0.28% | 2.11 M | 2026-05-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.27% | 2.04 M | 2026-05-31 |
| PAGANELLI JOHN A (Direct… | ≈0.05% | 403 515 | 2026-03-20 |
| FROST PHILLIP MD ET AL (… | — | — | 2025-11-21 |
